Tumor Treating Fields (EFE-P100)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Tumor Treating Fields (EFE-P100), covering 2022-12-22 to 2022-12-22. Get the full timeline:
Most recent: Clinical Trial Update: Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment [Phase 2, Phase 3]